


CARLOS N. VELEZ, PHD 23 KING STREET, SUITE 209 CAMBRIDGE CB1 1AH UNITED KINGDOM


CARLOSNVELEZ@CONNEXINTX.CO.UK

CONNEXIN THERAPEUTICS LTD.

DEVELOPING DRUGS THAT PRESERVE VISION AND PREVENT BLINDNESS



GROWING PREVALENCE DUE TO AGING




- Glaucoma prevalence growing rapidly, especially in Asia & Africa
 - Driven by aging population, smoking, and genetic factors


GLAUCOMA TREATMENTS & OPPORTUNITY

Modality	Examples	Pros	Cons
Drugs	Prostaglandins CA inhibitors Beta blockers	Easy to administer	Disease can still progress
Implants	Stents to prop canal open	Immediate reduction in pressure	Transient efficacy
Surgery	Laser	Same	Same

- Current global market ~\$7 billion
- Existing therapies can slow progression, but none protect remaining vision
- Product Concept: Drug coadministered with current glaucoma drugs to preserve remaining vision




SOLUTION: VISION PROTECTION




- Demonstrated vision protection in mice and primates with glaucoma with small molecule drugs
- We are blocking a protein called "connexin 36"
- Biology well understood and published

Sources: J Clin Invest. 2017;127(7), 2647-2661

NOVEL COMPOUNDS SHOW PROMISE



- Novel compounds being synthesized and tested in a low throughput retinal assay
- CxTx001 shows dose-response effect and will protect vision
- Further optimization will improve potency



HISTORY, FINANCING, AND RESEARCH PLAN

HISTORY


(19) United States

(12) Patent Application Publication (10) Pub. No.: US 2017/0106047 A1 BLOOMFIELD (43) Pub. Date: Apr. 20, 2017

(54)	METHODS OF USING GAP JUNCTIONS AS THERAFEUTIC TARGETS FOR THE TREATHENT OF DEGENERATIVE DISORDERS OF THE RETINA		Publication Classification (51) Int. CL. 			
(71)	Applicant:	THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK, Albany, NY (US)		A61K 900 (2006.01) A61K 31/7105 (2006.01) C12N 15/113 (2006.01)		
(72)	Inventor:	Stewart BLOOMFIELD, New York, NY (US)	(52)	CPC A61K 38/177 (2013.01); A61K 31/7105		
(73)	Assignee:	THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK, Albany, NY (US)	(2013.01); CI2N I5/II38 (2013.01); A6IK 9/0048 (2013.01); A6IK 45/06 (2013.01); CI2N 2320/31 (2013.01); CI2N 2310/11 (2013.01)			
(21)	Appl. No.:	15/317,171				
(22)	PCT Filed	Jun. 11, 2015	(57)	ABSTRACT		
(86)	PCT No.: § 371 (c)((2) Date:	PCT/US2015/035226 1), Dec. 8, 2016		The disclosure provides methods of treating a condition of the retina by administering an inhibitor of connexin 36		
	Related U.S. Application Data		and/or an inhibitor of connexin 45 to a subject with a retinal			
(60)			condition. This disclosure further provides compositions for the treatment of a retinal condition which include an inhibi- tor of connexin 36 and/or an inhibitor of connexin 45.			


- Founded Oct, 2018
- Exclusive license to IP and know how from Dr.
 Bloomfield's Lab
- Raised £150,000 May, 2019
- Synthesizing and testing novel connexin 36 inhibitors

RAISING £2.5 MILLION "SEED B"




- Deliverable: Optimized connexin 36 inhibitors backed by efficacy data in three animal models of glaucoma
- Timeline: 24-36 months with well-defined milestones
- Pipeline: Will also identify a Cx45 inhibitor for retinopathies


BUDGET DETAILS AVAILABLE BY REQUEST



- Over 60% of budget directed towards R&D...and includes contingencies
- Budget constructed from service provider proposals
- Projected UK R&D Tax credits exceeding £400k
- Grants not included in budget



COMPANY EVOLUTION



DON'T TAKE OUR WORD FOR IT....

E Menu Q Search Research & Development > Partnering > What we are looking fo

Ophthalmology



Our strategy in ophthalmology focuses on sight robbing "back of the eye" diseases. They include: Age-Related Macular Degeneration (AMD), Diabetic Retinopathy (DR), and Diabetic Macular Edema (DME)

Dry AMD and related Geographic Atrophy (GA) make up over 90% of AMD cases but have no currently approved therapy. The scientists at Roche are committed to the development of therapy for these retinal diseases and seek drug candidates with neuro-protective and retinal epithelial preserving properties. In addition, we also actively seek novel therapies for the wet form AMD, Diabetic Macular Edema, and other related diabetic retinal complications that would commente our CPL tocentis

(ranibizumab) franchise

Other diseases where we have a more opportunistic approach include Retinitis of Prematurity, Retinitis Pigmentosa, Uveitis, and Dry Eye. In Glaucoma we are particularly interested in therapies that have demonstrated the ability to protect retinal neurons compared to intraocular pressure lowering therapies.

If you have a promising drug candidate in the area of neuroscience, why not > submit your idea, meet us at a > conference or contact t⁽²⁾ virani.shafique@gene.com, Head of Neuroscience, Ophthalmology and Rare Diseases (NORD). > Ophthalmology pipeline

"In Glaucoma we are particularly interested in therapies that have demonstrated the ability to protect retinal neurons compared to intraocular pressure lowering therapies."

- Numerous multi-national pharma companies (Roche, Bayer, J&J, etc.) are seeking drugs which protect vision...recognizing the unmet medical need
- Provides an early opportunity for licensing or trade sale

NO COMPETITION IN CONNEXIN INHIBITION

Name	Company	Indication	Target	Phase	Molecule	Route
HCB1019	OcuNexus	Dry & Wet AMD, GA, DME, Retinopathy	Cx43	II	Small	Oral
Peptagon	OcuNexus	Dry & Wet AMD, GA, DME, Retinopathy	Cx43	Preclinical	Peptide	Intraocular
Nexagon	Eyevance	Diabetic Foot & Chronic Venous Ulcers	Cx43	Suspended	Antisense	Topical
Nexagon	Eyevance	Persistent Corneal Epithelial Defects	Cx43	II	Antisense	Topical

- Extensive competitive analysis available in full business plan
- Summary: Nobody else targeting connexin 36 for glaucoma

FOUNDERS



- Carlos N. Velez, Ph.D., Co-Founder & CEO
- Managing Partner, Lacerta Bio Business development consultancy
- Formerly Genencor, Penwest Pharma, Huron Consulting
- Split time between Cambridge, UK and New York, USA




- Stewart Bloomfield, Ph.D., Co-Founder and CSO
- Professor, SUNY Optometry Molecular & cellular processes in glaucoma
- Former Professor of Neuroscience & Ophthalmology, NYU
- Based in New York, USA



Christopher Hill, Co-Founder and CFO

- Independent CFO/Economist for Private & Listed biotech companies
- Former ORA Capital, Oxford Pharmascience, Others
- Based in York, UK



CARLOS N. VELEZ, PHD 23 KING STREET, SUITE 209 CAMBRIDGE CB1 1AH UNITED KINGDOM

CARLOSNVELEZ@CONNEXINTX.CO.UK

CONNEXIN THERAPEUTICS LTD.

DEVELOPING DRUGS THAT PRESERVE VISION AND PREVENT BLINDNESS